Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aspacytarabine - Ayala Pharmaceuticals

Next Previous
Search
Drug Profile

Aspacytarabine - Ayala Pharmaceuticals

Alternative Names: Ara-C asparagine conjugate; Aspacytarabine-hydrochloride-Ayala Pharmaceuticals; Asparagine ara-C conjugate; Asparagine cytarabine conjugate; Astarabine; BSR-236; BST 236; BST-236-HCl; Cytarabine asparagine conjugate; Cytarabine-prodrug

Latest Information Update: 11 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioSight
  • Developer Ayala Pharmaceuticals; Groupe Francophone des Myelodysplasies
  • Class Amino acids; Antineoplastics; Arabinonucleosides; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 04 Apr 2024 Ayala Pharmaceuticals files for patent protection for Aspacytarabine in Australia, Brazil, Canada, China, Europe, India, Japan, Israel, Russia, Korea, Hong Kong and the United States
  • 04 Apr 2024 Ayala Pharmaceuticals has patent protection for BST 236 composition and use in United States, Europe, Australia, Israel, Canada, Japan, Russia, India, Macau, China and Monaco
  • 04 Apr 2024 Ayala Pharmaceuticals has patents pending for Aspacytarabine polymorph in USA, Europe, Israel, Australia, Brazil, Canada, China, Hong Kong, India, Japan and South Korea

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top